Clinical Trial

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2027-02 -> 2027-04 2026-05-20
minor Completion pushed: 2029-12 -> 2030-02 2026-05-20
critical Recruitment opened 2026-05-14
notable Enrollment increased: 360 -> 460 participants 2026-05-14
Trial Details
NCT Number NCT07226843
Lead Sponsor Eli Lilly and Company
Conditions Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Enrollment 460 participants
Start Date 2026-04-17
Primary Completion 2027-04 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-06